Anthera Pharmaceuticals, a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, announced today that regulatory discussions with the US Food and Drug Administration (FDA) for the global development of blisbimod have completed Phase 2. Submission of Phase 3 protocols and the initiation of registration studies can now begin.
“We appreciate the FDA’s rapid response to our development proposal for blisibimod. We will incorporate their comments and begin the initiation of our Phase 3 lupus program,” said Paul F. Truex, Anthera’s President and CEO. “The PEARL-SC clinical study provided meaningful insight into the importance of selecting an appropriate patient population while also defining a meaningful endpoint. We are grateful the FDA found this approach to be acceptable for further study and look forward to bringing blisibimod one step closer to patients in need.”
The Phase 3 studies (CHABLIS-SC1 and CHABLIS-SC2) will consist of multicenter, placebo-controlled, randomized, double-blind studies designed for the evaluation of the efficacy, safety, tolerability, and immunogenicity of blisbimod when used in patients with clinically active SLE (SELENA-SLEDAI > 10) who have yet to achieve ideal resolution of their disease through the use of corticosteroids. Patients will receive treatment for 52 weeks in the controlled portion of each study. After this portion is completed, patients will have the option to continue receiving treatment as part of an open-label, long-term, follow-up safety study. The primary endpoint of the CHABLIS studies will be a Systemic Lupus Erythematosus Response Index (SRI*), including the requirement of an eight-point or greater improvement from baseline in the SELENA/SLEDAI disease measurement (SRI-8).
“The use of an SRI-8 endpoint, in a population with higher baseline disease activity requires patients to demonstrate improvement in the clinical presentations of SLE, such as skin, mucosal, joint disease and kidney disease,” said Colin Hislop, Anthera’s Chief Medical Officer. “For example, the blisibimod 200 mg weekly dose reduced proteinuria by nearly 1 gram per 24 hours at Week 24 compared with minimal change in the placebo group. This corresponds to an approximate 50% decrease from baseline. These types of improvements were responsible for the majority of clinical benefits seen in the PEARL-SC study and highlights blisibimod’s potential to help patients with more active disease.”
As previously reported, results from the PEARL-SC study indicate that in the predefined population of patients with clinically active disease (SELENA-SLEDAI > 10) who were also taking corticosteroids, the SRI-8 treatment benefit in the 200 mg weekly blisibimod cohort was statistically significant at week eight (22.6% blisibimod response versus 6.4% placebo response, p=0.023) and at week 16 (35.4% blisibimod response versus 17.0% placebo response, p=0.04) through the 24 week endpoint (41.7% blisibimod response versus 10.4% placebo response, p<0.001). Results from the PEARL-SC clinical study have been submitted to the American College of Rheumatology for presentation at the ACR/ARHP Annual Scientific Meeting 2012 in Washington, D.C.
For further information, please visit www.anthera.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for "The QualityStocks Daily Newsletter" at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks "Ones to Watch" http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment